UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 6, 2015

COHERUS BIOSCIENCES, INC.

(Exact name of registrant as specified in its charter)

Delaware	**001-36721**	**27-3615821**
(State or other jurisdiction of incorporation)	**(Commission File Number)**	**(IRS Employer Identification Number)**

201 Redwood Shores Parkway, Suite 200
Redwood City, CA 94065
(Address of principal executive offices, including Zip Code)

Registrant's telephone number, including area code: (650) 649-3530

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 2.02 Results of Operations and Financial Conditions

On August 10, 2015, Coherus BioSciences, Inc. (the "Company") issued a press release reporting its financial results for its second quarter ended June 30, 2015. The full text of the press release is furnished as Exhibit 99.1 to this Form 8-K.

This information in this Item 2.02 of this Form 8-K and the Exhibit 99.1 attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

On August 6, 2015, the Compensation Committee of the Board of Directors of the Company approved the following annual base salaries, effective as of July 1, 2015 for the named executive officers of the Company, as identified the Company's final Prospectus related to its secondary public offering, which was filed with the Securities and Exchange Commission pursuant to Rule 424(b) under the Securities Act of 1933, as amended, on April 1, 2015:

Executive Name	Position	2014 Base Salary	New Base Salary Effective July 1, 2015
Dennis M. Lanfear	President & Chief Executive Officer	$ 450,000	$ 561,700
Barbara K. Finck, M.D	Chief Medical Officer	$ 375,000	$ 407,500
Alan C. Herman, Ph.D.	Chief Scientific Officer	$ 350,000	$ 412,000
Peter K. Watler, Ph.D.	Chief Technology Officer	$ 335,000	$ 341,700
Jean-Frédéric Viret, Ph.D.	Chief Financial Officer	$ 350,000	$ 373,000

The Company will provide additional information regarding the compensation paid to the named executive officers for fiscal year 2015 in its definitive proxy statement for the 2016 Annual Meeting of Stockholders, which is expected to be filed with the Securities and Exchange Commission in the second quarter of 2016.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.	Description
99.1	Press Release dated August 10, 2015

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: August 10, 2015

COHERUS BIOSCIENCES, INC.

By: /s/ Jean-Frédéric Viret
Name: Jean-Frédéric Viret
Title: Chief Financial Officer

EXHIBIT INDEX

Exhibit No.	Description
99.1	Press Release dated August 10, 2015

Exhibit 99.1

Coherus BioSciences Reports Second Quarter 2015 Financial and Operating Results

Pegfilgrastim BLA-Enabling Studies Progressing and Etanercept Phase 3 Studies Enrolled

REDWOOD CITY, Calif., August 10, 2015 — Coherus BioSciences, Inc. (Nasdaq: CHRS), a leading pure-play, global biosimilars company with late-stage clinical products, today reported financial results and reviewed corporate events for the second quarter ended June 30, 2015.

Highlights include:

- CHS-1701 (pegfilgrastim (Neulasta®) biosimilar): In May 2015, Coherus completed the enrollment of its pivotal pharmacokinetic (PK) and pharmacodynamic (PD) study, which, if positive, could support the filing of a 351(k) biologics license application (BLA). An additional immunogenicity study is underway in healthy volunteers pursuant to this BLA and is projected to conclude dosing in 2015 to support submission of the BLA in the fourth quarter of 2015 or the first quarter of 2016.
- CHS-0214 (etanercept (Enbrel®) biosimilar): In May 2015, Coherus completed the enrollment for CHS-0214 Phase 3 clinical studies in rheumatoid arthritis and in psoriasis, for which Coherus received a $35 million milestone payment from Baxalta, formerly Baxter. In April 2015, Baxalta and Coherus announced an amendment to their CHS-0214 etanercept biosimilar collaboration agreement. In aggregate, the revised milestone payments may exceed the previous Baxalta funding obligations by approximately $12 million.
- In April 2015, Coherus consummated a follow-on public offering of $120.0 million of common stock, raising approximately $112.2 million in net proceeds. The proceeds from this follow-on public offering are being used to advance Coherus' second wave pipeline products beyond its initial three first wave products, and for general corporate purposes.

"Coherus completed the enrollment of its pegfilgrastim PK/PD BLA-enabling study and expects to read out top-line data for this study in the third quarter," said Denny Lanfear, president and chief executive officer of Coherus. "We expect that we will be in position to file a BLA for CHS-1701 in the fourth quarter of 2015 or the first quarter of 2016."

Second Quarter 2015 Financial Results

Total revenue for the second quarter 2015 was $6.9 million, as compared to $5.0 million in the second quarter of 2014. Total revenue for the six months ended June 30, 2015 was $12.7 million, as compared to $8.6 million for the same period in 2014. The higher revenue in the second quarter and first half of 2015 over the same periods in 2014 was due to the recognition of increased Baxalta collaboration revenue as a result of milestone payments received and amortized over the past 12 months.

Research and development (R&D) expenses for the second quarter 2015 were $56.9 million, compared with $18.9 million for the same period in 2014. R&D expenses for the six months ended June 30, 2015 were $93.4 million, as compared to $32.9 million for the same period in 2014. Increases in R&D expenses over the same periods were mainly attributable to an increase in program costs associated with the advancement of Coherus' late-stage clinical product candidates, CHS-0214, CHS-1701, and CHS-1420 (adalimumab (Humira®) biosimilar).

General and administrative (G&A) expenses for the second quarter 2015 were $8.8 million, compared to $4.0 million for the same period in 2014. G&A expenses for the six months ended June 30, 2015 were $14.9 million, as compared to $7.4 million for the same period in 2014. Increases in G&A expenses over the same periods were mainly attributable to increased employee-related expenses and increased legal and accounting services in support of being a public company.

Net loss attributable to Coherus for the second quarter 2015 was $58.8 million, or $1.56 per share, compared to $25.0 million, or $5.96 per share, for the same period in 2014.

Cash and cash equivalents totaled $206.1 million as of June 30, 2015, compared to $115.1 million at March 31, 2015 and $150.4 million at December 31, 2014.

Anticipated Near Term Milestones

- CHS-1701 (pegfilgrastim biosimilar): File 351(k) BLA in the U.S. in the fourth quarter of 2015 or the first quarter of 2016.
- CHS-1420 (adalimumab biosimilar): Initiate Phase 3 clinical study in psoriasis in mid-2015; initiate PK bioequivalence bridging study by the end of the first half of 2016 with Phase 3 drug material; file BLA in the U.S. in the second half of 2016.
- CHS-0214 (etanercept biosimilar): Topline data for the psoriasis Phase 3 study in the fourth quarter of 2015 and for the rheumatoid arthritis study in the first quarter of 2016. We are expecting to file a Marketing Authorization Application (MAA) in the E.U. in 2016.

Conference Call Information

When: August 10, 2015, 1:30 p.m. PT
Dial-in: (844) 452-6826 (domestic) or (765) 507-2587 (international)
Conference ID: 86021327
Webcast: http://investors.coherus.com
Please join the conference call at least 10 minutes early to register.
The webcast of the conference call will be available for replay through August 24, 2015.

About Coherus BioSciences, Inc.

Coherus is a pure-play biosimilar platform company that develops and commercializes high-quality therapeutics for major regulated markets. Biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and expand patient access. Composed of a team of proven industry veterans with world-class expertise in process science, analytical characterization, protein production and clinical-regulatory development, Coherus is positioned as a leader in the global biosimilar marketplace. Coherus is advancing three late-stage clinical products towards commercialization, CHS-1701 (pegfilgrastim biosimilar), CHS-0214 (etanercept biosimilar) and CHS-1420 (adalimumab biosimilar), as well as developing a robust pipeline of future products. For additional information, please visit www.coherus.com.

Forward-Looking Statements

Except for the historical information contained herein, the matters set forth in this press release, including statements regarding Coherus' plans, potential opportunities, expectations, projections, goals, objectives, milestones, strategies, product pipeline, clinical studies, product development, release of data and the potential benefits of its products under development are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including Coherus' expectations regarding its ability to advance its CHS-1701, CHS-0214 and CHS-1420 biosimilar drug candidates, initiate the Phase 3 clinical study in psoriasis and the PK bioequivalence study for CHS-1420, complete its BLA-enabling studies for CHS-1701, file BLAs for CHS-1701 and CHS-1420 in the U.S., file an MAA for CHS-0214 in the E.U., receive milestone payments under its collaboration agreement with Baxalta and advance Coherus' product pipeline. Such forward-looking statements involve substantial risks and uncertainties that could cause our clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the clinical drug development process, including the regulatory approval process, the timing of our regulatory filings and other matters that could affect the availability or commercial potential of our biosimilar drug candidates. Coherus undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Coherus' business in general, see Coherus' Quarterly Report on Form 10-Q for the quarter ended March 31, 2015, filed with the Securities and Exchange Commission on May 11, 2015, and its future periodic reports to be filed with the Securities and Exchange Commission.

Coherus BioSciences, Inc.
Condensed Consolidated Statements of Operations
(in thousands, except share and per share data)

	Three Months Ended June 30,		Six Months Ended June 30,	
	2015	2014	2015	2014
	(unaudited)		*(unaudited)*	
Revenue:				
Collaboration and license revenue	$ 6,866	$ 4,458	$ 12,676	$ 7,548
Collaboration and license revenue - related party (1)	—	507	—	1,013
Total revenue	6,866	4,965	12,676	8,561
Operating expenses:				
Research and development	56,944	18,925	93,411	32,861
General and administrative	8,817	3,978	14,908	7,399
Total operating expenses	65,761	22,903	108,319	40,260
Loss from operations	(58,895)	(17,938)	(95,643)	(31,699)
Interest expense	—	(1,158)	—	(3,899)
Other expense, net	(139)	(5,974)	(4,230)	(14,642)
Net loss	(59,034)	(25,070)	(99,873)	(50,240)
Net loss attributable to non-controlling interest	224	113	338	113
Net loss attributable to Coherus	$ (58,810)	$ (24,957)	$ (99,535)	$ (50,127)
Net loss per share attributable to Coherus, basic and diluted	$ (1.56)	$ (5.96)	$ (2.80)	$ (11.99)
Weighted-average number of shares used in computing net loss per share attributable to Coherus, basic and diluted	37,672,748	4,186,822	35,536,889	4,182,053

(1) Represent revenue from Daiichi Sankyo Company, a holder of more than 10% of our common stock until the closing of our initial public offering on November 12, 2014.

Coherus BioSciences, Inc.
Condensed Consolidated Balance Sheets
(in thousands)

	June 30, 2015 *(unaudited)*	December 31, 2014
Assets		
Cash and cash equivalents	$206,088	$ 150,392
Other assets	43,458	36,829
Total assets	$249,546	$ 187,221
Liabilities and Stockholders' Equity		
Deferred revenue	69,496	62,699
Other liabilities	83,686	57,765
Total stockholders' equity	96,364	66,757
Total liabilities and stockholders' equity	$249,546	$ 187,221

CONTACT: Keith Vendola
Investor Relations
Coherus BioSciences, Inc.
kvendola@coherus.com
+1 (650) 437-6239